CLVS Stock Overview
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
+ 1 more risk
Clovis Oncology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.70|
|52 Week High||US$6.64|
|52 Week Low||US$0.58|
|1 Month Change||146.38%|
|3 Month Change||10.39%|
|1 Year Change||-74.01%|
|3 Year Change||-88.57%|
|5 Year Change||-98.18%|
|Change since IPO||-86.47%|
Recent News & Updates
Clovis: Shifting Toward Nuclear Medicine
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a trading stock, Clovis shares are still changing hands at a deep valuation to their true value.
|CLVS||US Biotechs||US Market|
Return vs Industry: CLVS underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: CLVS underperformed the US Market which returned -18.4% over the past year.
|CLVS Average Weekly Movement||26.2%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CLVS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.
Volatility Over Time: CLVS's weekly volatility has increased from 16% to 26% over the past year.
About the Company
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology Fundamentals Summary
|CLVS fundamental statistics|
Is CLVS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLVS income statement (TTM)|
|Cost of Revenue||US$33.26m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.80|
|Net Profit Margin||-178.28%|
How did CLVS perform over the long term?See historical performance and comparison
Is CLVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLVS?
Other financial metrics that can be useful for relative valuation.
|What is CLVS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CLVS's PS Ratio compare to its peers?
|CLVS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
LCTX Lineage Cell Therapeutics
BNR Burning Rock Biotech
AADI Aadi Bioscience
VYGR Voyager Therapeutics
CLVS Clovis Oncology
Price-To-Sales vs Peers: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (28.1x).
Price to Earnings Ratio vs Industry
How does CLVS's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is CLVS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.7x|
|Fair PS Ratio||15.6x|
Price-To-Sales vs Fair Ratio: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (15.6x).
Share Price vs Fair Value
What is the Fair Price of CLVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CLVS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CLVS's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLVS's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at our analysis of CLVS's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLVS's revenue (32% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CLVS's revenue (32% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLVS is forecast to be unprofitable in 3 years.
Discover growth companies
How has Clovis Oncology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLVS is currently unprofitable.
Growing Profit Margin: CLVS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLVS is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Clovis Oncology's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLVS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CLVS has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.9% each year.
Discover healthy companies
What is Clovis Oncology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CLVS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Mahaffy (58 yo)
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.
Experienced Management: CLVS's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: CLVS's board of directors are seasoned and experienced ( 13.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.6%.
Clovis Oncology, Inc.'s employee growth, exchange listings and data sources
- Name: Clovis Oncology, Inc.
- Ticker: CLVS
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$244.595m
- Shares outstanding: 143.88m
- Website: https://www.clovisoncology.com
Number of Employees
- Clovis Oncology, Inc.
- 5500 Flatiron Parkway
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.